Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin with Trastuzumab and Pertuzumab in HER2+ Breast Cancer
NCT01912963Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Sep 2013
- Primary completion
- Dec 2016
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in HER2-positive breast cancer, sponsored by Dana-Farber Cancer Institute. Started Sep 2013; status: terminated.
02
Drugs
eribulin
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01912963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01912963.